Literature DB >> 17154344

Comparison of military and civilian reporting rates for smallpox vaccine adverse events.

A W McMahon1, C Zinderman, R Ball, G Gupta, M M Braun.   

Abstract

INTRODUCTION: US smallpox vaccination (SMA) started most recently in December 2002. Military and civilian personnel report adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS), a surveillance system that relies on spontaneous reports. Although reported rates of probable myo/pericarditis after SMA in the literature are similar between military personnel and civilian healthcare workers, some civilian AE reporting rates after SMA appeared higher than those in the military.
OBJECTIVE: Determine if SMA-associated reporting rates are different in civilians than in the military, considering age, sex, seriousness, and expectedness of the AE, as well as self-reporting.
METHODS: Numerators were SMA reports in VAERS from 12/12/02 to 3/1/04. Limitations of VAERS include underreporting and lack of diagnostic confirmation. Denominators were number of military and civilian vaccinees.
RESULTS: Reporting rates stratified by age and sex of serious and non-serious AEs were significantly higher in civilian than military personnel ages <55 years (rate ratios 4-27). These rate ratios decreased with increasing age.
CONCLUSIONS: Reporting rates in VAERS differed significantly and substantially in civilians compared to military personnel <55 years of age. Differences in stimulated passive surveillance systems, and AE reporting practices, including the 'threshold' for reporting most likely explain these findings. These results suggest that in the case of smallpox vaccine AEs, there may be systematic differences in reporting completeness between the civilian and military sectors, and that passive surveillance data should be interpreted with caution. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17154344     DOI: 10.1002/pds.1349

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

Authors:  Michael M McNeil; Maria Cano; Elaine R Miller; Brett W Petersen; Renata J M Engler; Marthe G Bryant-Genevier
Journal:  Vaccine       Date:  2014-06-18       Impact factor: 3.641

2.  Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.

Authors:  Barbara H Bardenheier; Susan K Duderstadt; Renata J M Engler; Michael M McNeil
Journal:  Vaccine       Date:  2016-07-19       Impact factor: 3.641

3.  A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.

Authors:  Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Brian A Hemann; Barnett T Gibbs; J Edwin Atwood; Robin S Howard; Audrey S Chang; Daniel L Cruser; Daniel G Gates; Marina N Vernalis; Marguerite S Lengkeek; Bruce M McClenathan; Allan S Jaffe; Leslie T Cooper; Steve Black; Christopher Carlson; Christopher Wilson; Robert L Davis
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

4.  Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis.

Authors:  Ryan Ruiyang Ling; Kollengode Ramanathan; Felicia Liying Tan; Bee Choo Tai; Jyoti Somani; Dale Fisher; Graeme MacLaren
Journal:  Lancet Respir Med       Date:  2022-04-11       Impact factor: 102.642

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.